Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Armata Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LOS ANGELES, AUG. 12, 2026 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS SECOND QUARTER ENDED JUNE 30, 2026, AND PROVIDED A CORPORATE UPDATE. "WE CONTINUE TO FINALIZE ACTIVITIES REQUIRED TO INITIATE A PIVOTAL PHASE 3 SUPERIORITY STUDY OF AP-SA02 IN COMPLICATED S.

ARMATA PHARMACEUTICALS ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER 2026 AND PROVIDES A CORPORATE UPDATE

FDA SUBMISSIONS ADDRESS ALL FEEDBACK ON CLINICAL, CMC, AND REGULATORY TOPICS FROM THE END-OF-PHASE 2 MEETING FOUR AP-SA02 ENGINEERING RUNS COMPLETED; CLINICAL TRIAL MATERIAL PRODUCTION IS THE NEXT PLANNED MANUFACTURING STEP PHASE 3 SUPERIORITY STUDY REMAINS ON TRACK TO INITIATE IN THE SECOND HALF OF 2026 LOS ANGELES, JULY 20, 2026 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS,TODAY ANNOUNCED SIGNIFICANT CLINICAL, REGULATORY, MANUFACTURING AND OPERATIONAL PROGRESS SUPPORTING ADVANCEMENT OF AP-SA02, THE COMPANY'S INTRAVENOUSLY ADMINISTEREDSTAPHYLOCOCCUS AUREUS("S. AUREUS") MULTI-PHAGE PRODUCT CANDIDATE, TOWARD A PLANNED PHASE 3 SUPERIORITY STUDY FOR ADJUNCT TREATMENT OF COMPLICATED BACTEREMIA CAUSED BY METHICILLIN-SENSITIVES.

ARMATA PHARMACEUTICALS ACHIEVES KEY PROGRESS ACROSS CLINICAL, REGULATORY AND MANUFACTURING ACTIVITIES SUPPORTING PLANNED PHASE 3 INITIATION OF AP-SA02

FULFILLS IMPORTANT REGULATORY MILESTONE FOR AP-SA02 ON THE PATH TOWARD A FUTURE BLA AND SUPPORTS EXPANSION INTO PEDIATRIC PATIENTS LOS ANGELES, JULY 13, 2026 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THAT IT HAS RECEIVED AGREEMENT FROM THE U.S. FOOD AND DRUG ADMINISTRATION (THE "FDA") ON AN AGREED INITIAL PEDIATRIC STUDY PLAN ("AGREED IPSP"), WHICH ESTABLISHES THE AGREED REGULATORY FRAMEWORK FOR THE FUTURE EVALUATION OF AP-SA02 FOR THE ADJUNCT TREATMENT OF COMPLICATED STAPHYLOCOCCUS AUREUSBACTEREMIA ("SAB") IN PEDIATRIC PATIENTS. AGREEMENT WITH THE FDA ON AN IPSP IS A REGULATORY REQUIREMENT THAT MUST BE MET PRIOR TO SUBMITTING A BIOLOGICS LICENSE APPLICATION ("BLA").

ARMATA PHARMACEUTICALS RECEIVES AGREEMENT FROM FDA ON INITIAL PEDIATRIC STUDY PLAN FOR AP-SA02 FOR THE TREATMENT OF COMPLICATED STAPHYLOCOCCUS AUREUS BACTEREMIA

SUPPORTS PHASE 3 READINESS OF AP-SA02 NON-DILUTIVE DOD FUNDING TOTALS $28.7M TO DATE LOS ANGELES, JUNE 23, 2026 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN:ARMP) ("ARMATA" OR THE "COMPANY"), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THAT IT HAS RECEIVED AN ADDITIONAL $2.5 MILLION OF NON-DILUTIVE FUNDING PURSUANT TO A PREVIOUSLY ANNOUNCED DEPARTMENT OF DEFENSE (DOD) AWARD, RECEIVED THROUGH THE MEDICAL TECHNOLOGY ENTERPRISE CONSORTIUM (MTEC) AND MANAGED BY THE NAVAL MEDICAL RESEARCH COMMAND (NMRC)  NAVAL ADVANCED MEDICAL DEVELOPMENT (NAMD) WITH FUNDING FROM THE DEFENSE HEALTH AGENCY AND JOINT WARFIGHTER MEDICAL RESEARCH PROGRAM. THE AWARD, WHICH NOW TOTALS $28.7 MILLION, SUPPORTS THE DEVELOPMENT OF ARMATA'S LEAD CLINICAL CANDIDATE AP-SA02, FOR ADJUNCT TREATMENT OF COMPLICATED STAPHYLOCOCCUS AUREUS ("S.

ARMATA PHARMACEUTICALS RECEIVES $2.5 MILLION OF ADDITIONAL NON-DILUTIVE AWARD FUNDING FROM THE U.S. DEPARTMENT OF DEFENSE TO SUPPORT AP-SA02

ENTERED INTO SECURED CREDIT AGREEMENT WITH INNOVIVA FOR $25 MILLION MATURING IN 2029 LOS ANGELES, MAY 13, 2026 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A CORPORATE UPDATE. "OUR TOP PRIORITY IN 2026 IS ADVANCING ARMATA'S LEAD STAPHYLOCOCCUS AUREUS ("S.

ARMATA PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2026 RESULTS AND PROVIDES CORPORATE UPDATE

ENABLES MORE FREQUENT FDA ENGAGEMENT, ROLLING BIOLOGIC LICENSE APPLICATION REVIEW, AND THE POTENTIAL FOR ACCELERATED APPROVAL AND PRIORITY REVIEW UPON SUCCESSFUL CLINICAL DEVELOPMENT ADVANCES AP-SA02 ON A FASTER PATH TO POTENTIAL APPROVAL AND PATIENT ACCESS LOS ANGELES, MAY 7, 2026 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (THE "FDA") HAS GRANTED FAST TRACK DESIGNATION TO AP-SA02, THE COMPANY'S INTRAVENOUSLY ADMINISTERED STAPHYLOCOCCUS AUREUS ("S. AUREUS") MULTI-PHAGE PRODUCT CANDIDATE, FOR ADJUNCT TREATMENT OF COMPLICATED BACTEREMIA CAUSED BY METHICILLIN-SENSITIVE S.

ARMATA PHARMACEUTICALS SECURES FDA FAST TRACK DESIGNATION FOR AP-SA02

DESCRIBES STRUCTURE OF PHAGE P7-1, INCLUDED IN ARMATA'S PSEUDOMONAS AERUGINOSA PHAGE COCKTAIL, AP-PA02 LOS ANGELES, MAY 4, 2026 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED A PAPER IN COMMUNICATIONS BIOLOGY, A PEER-REVIEWED JOURNAL FROM NATURE PORTFOLIO. THE PUBLICATION, TITLED, "STRUCTURAL ATLAS OF PAKPUNAVIRUS P7-1 REVEALS DETERMINANTS OF VIRION STABILITY AND GENOME EJECTION," DESCRIBES THE STRUCTURE OF PHAGE P7-1, WHICH IS INCLUDED IN ARMATA'S MULTI-PHAGE COCKTAIL, AP-PA02.

ARMATA PHARMACEUTICALS ANNOUNCES STRUCTURAL BIOLOGY PUBLICATION IN "COMMUNICATIONS BIOLOGY"

LOS ANGELES, APRIL 27, 2026 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THAT DANIEL B. GILMER, PH.D.

ARMATA PHARMACEUTICALS ANNOUNCES APPOINTMENT OF BIOPHARMACEUTICAL COMMERCIAL EXECUTIVE DANIEL B. GILMER, PH.D.

LOS ANGELES, MARCH 25, 2026 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS FOURTH QUARTER AND FULL-YEAR ENDED DECEMBER 31, 2025. FOURTH QUARTER 2025 FINANCIAL RESULTS GRANT REVENUE.

ARMATA PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS

LOS ANGELES, MARCH 19, 2026 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THAT IT WILL DELAY THE ANNOUNCEMENT OF ITS FINANCIAL RESULTS FOR ITS FOURTH QUARTER AND FULL-YEAR ENDED DECEMBER 31, 2025, AND PROVIDED A CORPORATE UPDATE. THE COMPANY REQUIRES ADDITIONAL TIME TO COMPLETE ITS FINANCIAL REPORTING AND ANTICIPATES FILING ITS ANNUAL REPORT ON FORM 10-K ON OR BEFORE MARCH 31, 2026, THE DUE DATE.

Armata Pharmaceuticals, Inc.

ARMP

Price

Financial Reports

No items found.

Press Releases

Armata Pharmaceuticals, Inc.

ARMP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ARMP